Regarding antitumor therapy, CpG in conjunction with an anti-TLR2 antibody have been shown to induce the production of IFNγ and the migration of CD8 T and NK lymphocytes to the tumor stroma [36,37]. The gene discussed is CD8A; the disease is neoplasm.